115 related articles for article (PubMed ID: 32898013)
1. High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis.
Thi-Hai Pham Y; Utuama O; Thomas CE; Park JA; La Vecchia C; Risch HA; Tran CT; Le TV; Boffetta P; Raskin L; Luu HN
Eur J Cancer Prev; 2020 Nov; 29(6):565-581. PubMed ID: 32898013
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression.
Binabaj MM; Soleimani A; Rahmani F; Avan A; Khazaei M; Fiuji H; Soleimanpour S; Ryzhikov M; Ferns GA; Bahrami A; Hassanian SM
Gene; 2019 Jul; 706():131-139. PubMed ID: 31055021
[TBL] [Abstract][Full Text] [Related]
3. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
[TBL] [Abstract][Full Text] [Related]
4. High mobility group protein A2 overexpression indicates poor prognosis for cancer patients: a meta-analysis.
Nie D; Zhang L; Guo Q; Mao X
Oncotarget; 2018 Jan; 9(1):1237-1247. PubMed ID: 29416690
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: a meta-analysis.
Zhu J; Wang H; Xu S; Hao Y
Oncotarget; 2017 Nov; 8(59):100478-100489. PubMed ID: 29245994
[TBL] [Abstract][Full Text] [Related]
6. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets.
Huang B; Yang J; Cheng Q; Xu P; Wang J; Zhang Z; Fan W; Wang P; Yu M
Front Physiol; 2018; 9():776. PubMed ID: 29997523
[No Abstract] [Full Text] [Related]
8. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of HMGA2 gene expression for differentiation of malignant thyroid nodules: A systematic review and meta-analysis.
Kim BH; Kim SJ; Kim M; Lee SW; Jeong SY; Pak K; Kim K; Kim IJ
Clin Endocrinol (Oxf); 2018 Dec; 89(6):856-862. PubMed ID: 30223300
[TBL] [Abstract][Full Text] [Related]
10. The role of let-7 and HMGA2 in the occurrence and development of lung cancer: a systematic review and meta-analysis.
Li XX; Di X; Cong S; Wang Y; Wang K
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8353-8366. PubMed ID: 30556876
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.
Wei R; Shang Z; Leng J; Cui L
J Cancer Res Ther; 2016; 12(4):1291-1297. PubMed ID: 28169242
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of HMGA2, P16, and HPV in oral squamous cell carcinomas.
Loeschke S; Ohlmann AK; Bräsen JH; Holst R; Warnke PH
J Craniomaxillofac Surg; 2016 Sep; 44(9):1422-9. PubMed ID: 27421171
[TBL] [Abstract][Full Text] [Related]
13. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.
Liu Z; Wu K; Yang Z; Wu A
Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485
[TBL] [Abstract][Full Text] [Related]
14. High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition.
Lee J; Ha S; Jung CK; Lee HH
Int J Oncol; 2015; 46(6):2431-8. PubMed ID: 25845850
[TBL] [Abstract][Full Text] [Related]
15. HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer.
Jun KH; Jung JH; Choi HJ; Shin EY; Chin HM
Int J Surg; 2015 Dec; 24(Pt A):39-44. PubMed ID: 26537313
[TBL] [Abstract][Full Text] [Related]
16. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
17. Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2.
Li Y; Wang D; Ren H; Feng W
Thorac Cancer; 2020 Mar; 11(3):686-692. PubMed ID: 32031335
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic levels of high mobility group A2 determine survival prognoses in breast cancer patients.
Heilmann T; Vondung F; Borzikowsky C; Krüger S; Elessawy M; Alkatout I; Wenners A; Bauer M; Klapper W; Röcken C; Maass N; Schem C; Trauzold A
Int J Biol Markers; 2020 Jun; 35(2):20-28. PubMed ID: 32394766
[TBL] [Abstract][Full Text] [Related]
19. HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma.
Palumbo A; Da Costa NM; Esposito F; De Martino M; D'Angelo D; de Sousa VP; Martins I; Nasciutti LE; Fusco A; Ribeiro Pinto LF
Oncotarget; 2016 May; 7(18):25872-84. PubMed ID: 27027341
[TBL] [Abstract][Full Text] [Related]
20. The expressions of HMGA2 and Thy1 in extrahepatic cholangiocarcinoma and their clinicopathological significances.
Liu R; Yang Z; Huang S; Li D; Zou Q; Yuan Y
Surg Oncol; 2019 Jun; 29():41-47. PubMed ID: 31196492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
